Redwood Pharma

Redwood Pharma CEO Martin Vidaeus will attend BIO-Europe that will be held in Munich, Germany, between November 6-8. BIO-Europe is Europe's leading partnering event with over 5,500 participants representing 60 countries and over 2,200 companies. The conference creates a unique opportunity for Redwood Pharma to engage in discussions with potential partners.

"After the summer, we received the final results from the RP501 clinical study. We will bring along the robust data package generated by the study to our discussions with potential partners. This meeting will provide us a favorable oppportunity to evaluate possible commercial partners in self-care and ophthalmology for a launch of the product in Europe," says Redwood Pharma's CEO, Martin Vidaeus.

RP501 is being developed to be an effective and user-friendly over-the-counter tear replacement agent for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. RP501 is based on IntelliGel - a patented and unique formulation that has the consistency of a drop of water when instilled onto the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long period of time.